To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Select year:
Videos
A collection of videos showcasing recent developments and expert
insights from AANEM.
Richard’s perspective – Living with MMN
This video interview between Lisa Butler and Richard Sperry from the CIDP/GBS Foundation (US) describes Richard’s experience with MMN.
Brenda’s Multifocal Motor Neuropathy (MMN) Story
Brenda shares her experience living with MMN.
Idiopathic Inflammatory Myopathies (Myositis), Disease Pathogenesis
This mechanism of disease video details myositis; a systemic auto-immune rheumatic disease.
Efgartigimod, Mechanism of Action
This video illustrates efgartigimod’s differentiated mechanism of action.
Handouts
Downloadable resources with key insights and clinical updates from
AANEM experts.
ADHERE REAL Study Flyer
Awareness flyer for the ADHERE REAL study.
Empasiprubart MMN Card
Awareness flyer for the Empassion study.
ALS clinical study card
Awareness flyer for the ALS study
ALKIVIA clinical study card
Awareness flyer for the ALKIVIA study.
VYVGART Pregnancy study
Awareness flyer for the VYVGART Pregnancy study.
ADAPT OCULUS clinical study card
Awareness flyer for the ADAPT Oculus study.
Immunology Innovation Program flyer
This flyer contains information about argenx’s commitment to developing antibodies against novel targets through co-creation.
MMN Disease State Handout
This handout discusses disease state education around MMN including symptoms, disease burden, and pathophysiology.
Myositis Disease State Handout
This handout discusses disease state education around Myositis.
Efgartigimod Mechanism of Action Handout
This handout discusses efgartigimod and its proposed mechanism of action, not specific to a disease state.
ADAPT Oculus Study handout
argenx pipeline handout
This handout showcases argenx’s pipeline.
argenx Medical Affairs: Science of Collaboration Congress Handout
Empasiprubart 117 Proposed Mechanism of Action Handout
This handout discusses empasiprubart and its proposed mechanism of action, not specific to a disease state.
Poster/oral presentations 2025
Recent developments in the neuromuscular field.
Poster/oral presentations 2024
Recent developments in the neuromuscular field.
We couldnot find any results for your search.
Please consider trying a different term.
Items per page:
- 3
- 6
- 9
- 12
1-12 of 16
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2025 argenx MED-US-NON-2400036 V4 11/2025. All Rights Reserved.